Nantahala Capital Management buys $21,081,812 stake in SciClone Pharmaceuticals (SCLN)

SciClone Pharmaceuticals (SCLN) : Nantahala Capital Management scooped up 1,453,263 additional shares in SciClone Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 2,025,150 shares of SciClone Pharmaceuticals which is valued at $21,081,812.SciClone Pharmaceuticals makes up approximately 3.30% of Nantahala Capital Management’s portfolio.

Other Hedge Funds, Including , Parametric Portfolio Associates reduced its stake in SCLN by selling 88,806 shares or 41.68% in the most recent quarter. The Hedge Fund company now holds 124,268 shares of SCLN which is valued at $1,293,630. Stevens Capital Management Lp added SCLN to its portfolio by purchasing 11,944 company shares during the most recent quarter which is valued at $124,337.Blackrock Investment Management boosted its stake in SCLN in the latest quarter, The investment management firm added 42,382 additional shares and now holds a total of 219,053 shares of SciClone Pharmaceuticals which is valued at $2,280,342. Rational Advisors added SCLN to its portfolio by purchasing 10,750 company shares during the most recent quarter which is valued at $111,908. SciClone Pharmaceuticals makes up approx 0.08% of Rational Advisors’s portfolio.

SciClone Pharmaceuticals closed down -0.06 points or -0.60% at $10.01 with 4,46,929 shares getting traded on Thursday. Post opening the session at $10.04, the shares hit an intraday low of $9.84 and an intraday high of $10.155 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, SciClone Pharmaceuticals reported $0.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.14 according to the earnings call on Nov 9, 2015. Analyst had a consensus of $0.12. The company had revenue of $42.90 million for the quarter, compared to analysts expectations of $40.61 million. The company’s revenue was up 25.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.17 EPS.

SciClone Pharmaceuticals Inc. (SciClone) is a pharmaceutical company. The Company operates in two geographic segments including China and the rest of the world (the United States and Hong Kong). The Company’s lead product ZADAXIN (thymalfasin) is used for the treatment of hepatitis B virus (HBV) hepatitis C (HCV) as a vaccine adjuvant and certain cancers. Its development portfolio includes Angiomax an anticoagulant indicated in patients undergoing percutaneous coronary intervention (PCI); Neucardin therapeutic drug for the treatment of patients with intermediate to advanced chronic heart failure (CHF); Loramyc a mucoadhesive tablet formulation of miconazole lauriad to treat oropharyngeal candidiasis; Cleviprex a third-generation dihydropyridine calcium channel blocker for the reduction of blood pressure; ProFlow to treat peripheral arterial disease (PAD) and other indications and RapidFilm an oral film formulation of ondansetron to treat nausea induced by chemotherapy.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

SciClone Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on SciClone Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.